Advanced Nuclear Medicine Ingredients   Report issue

For profit Phase 3
Founded: Liege Belgium (2015)
Status: Acquired by Telix (2018)

Organization Overview

First Clinical Trial
2019
NCT03623425
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Advanced Nuclear Medicine Ingredients (ANMI)

Active Ingredients

Drugs in Phase 3 Trials (2)

fluorocholine (1 trial)

Ga 68 PSMA-11 (Illuccix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2